Clinical Trial Update: Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 feasibility study assessing individual pharmacokinetic-guided dosing of sunitinib in patients with advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Malignant Solid Tumour | Phase 1 | Status: COMPLETED